Effect of Dexmedetomidine on Acute Kidney Injury After Ascending Aortic Surgeries

Launched by AIN SHAMS UNIVERSITY · Apr 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called dexmedetomidine can help prevent acute kidney injury (AKI) in patients undergoing ascending aortic surgeries that require a heart-lung machine, known as cardiopulmonary bypass (CPB). AKI is a common and serious problem that can occur after these surgeries. The researchers want to see if giving dexmedetomidine before and during the surgery can reduce the risk of kidney injury by helping to lower inflammation and stress on the body.

To be eligible for this trial, participants need to be between the ages of 20 and 70 and scheduled for aortic surgery that involves CPB. Some individuals may not be able to participate if they have certain heart conditions or if their kidney function is already impaired. The trial will be conducted in a controlled way, meaning some participants will receive dexmedetomidine while others will receive a placebo (a treatment that looks the same but has no active ingredients) to compare the effects. The trial is not yet recruiting participants, but it aims to provide valuable insights into how to protect kidney health during important surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ●Age: 20-70 yrs
• • Scheduled for aortic surgery under CPB
• Exclusion Criteria:
• • ●Patient refusal to participate
• • Congestive heart failure with a left ventricular ejection fraction \<45%
• • Uncontrolled arrhythmia combined with unstable hemodynamics
• • Acute coronary syndrome.
• • Preoperative elevated kidney function (serum urea and serum creatinine). Use of ventricular assist devices